Enzo Biochem (ENZ) Gets NY DoH Approval for ColonSentry Test

Enzo Biochem, Inc. (NYSE: ENZ) today announced that the New York State Department of Health has approved Enzo Clinical Labs’ use of the ColonSentry test for providing an assessment of a patient’s risk of having colorectal cancer. The ColonSentry test was originally developed by GeneNews and requires only a small blood sample which can be collected during a routine blood draw. Enzo plans to begin offering the assay to its clientele in March 2012.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept
• Methanex to idle New Zealand plants in 2027, sells gas rights
• Xos Hub reaches 1 gigawatt-hour milestone from a single unit